Ambrilia says HIV protease inhibitor PPL-100 well-tolerated in phase 1a study

By Elaine Rigoli

Tampa, Fla., June 20 - Ambrilia Biopharma, Inc. said data from the phase 1a results for its lead HIV protease inhibitor PPL-100 confirmed PPL-100 to be very safe and well-tolerated up to 2,400 mg without any significant adverse events.

Only mild adverse events were observed in all cohorts, according to a news release.

Based on PPL-100's pharmacokinetic profile, its long half-life of more than 24 hours and expected single-dose to steady state pharmacokinetic ratio, PPL-100 could have the potential to be an un-boosted, once-a-day PI for treatment-experienced patients.

The company said it will start a phase 1b study, investigating safety and pharmacokinetics after repeated oral dosing (steady state) with PL-100, this summer.

Ambrilia is a biopharmaceutical company located in Montreal with a regional office in France.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.